Physician profile
Molly Friedman
NPI 1952487134
$4,986.55
in general payments reported to CMS, 2019-2025
39 companies · $1,505 in 2025
The $1,505 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $220 · 2021: $24.91 · 2022: $698 · 2023: $969 · 2024: $917 · 2025: $1,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,390.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,284.30 | 2022-2025 | |
| Lilly USA, LLC | $674.34 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $388.30 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $341.68 | 2019-2025 | |
| Astellas Pharma US INC | $321.16 | 2019-2025 | Veozah |
| Novo Nordisk INC | $255.28 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Exact Sciences Corporation | $196.00 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $194.32 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Amgen INC. | $182.54 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.35 | 2023-2025 | Jardiance, Ofev |
| Supernus Pharmaceuticals, INC. | $79.65 | 2019-2024 | Qelbree, Qelbree |
| Allergan, INC. | $76.56 | 2020 | |
| Currax Pharmaceuticals LLC | $64.61 | 2019-2024 | Contrave |
| Takeda Pharmaceuticals U.S.A., INC. | $55.60 | 2019-2020 | |
| Amarin Pharma, INC. | $52.42 | 2019-2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.